Banque Pictet & Cie Sa Bio N Tech Se Transaction History

Banque Pictet & Cie Sa

$14.9 Billion
Q4 2024

A detailed history of Banque Pictet & Cie Sa transactions in Bio N Tech Se stock. As of the latest transaction made, Banque Pictet & Cie Sa holds 2,070 shares of BNTX stock, worth $248,420. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,070

Previous 2,180 5.05%

Holding current value

$248,420

Previous $258,000 8.91%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 30, 2025	SELL	$99.72 - $122.68 $10,969 - $13,494	-110 Reduced 5.05%	2,070 $235,000
Q3 2024 Oct 21, 2024	BUY	$78.36 - $124.66 $170,824 - $271,758	2,180 New	2,180 $258,000
Q2 2023 Aug 04, 2023	SELL	$102.58 - $129.66 $522,850 - $660,877	-5,097 Reduced 59.36%	3,490 $376,000
Q1 2023 May 01, 2023	SELL	$122.57 - $153.67 $538,327 - $674,918	-4,392 Reduced 33.84%	8,587 $1.07 Million
Q4 2022 Feb 06, 2023	SELL	$118.43 - $186.05 $4.38 Million - $6.88 Million	-36,982 Reduced 74.02%	12,979 $0
Q3 2022 Nov 10, 2022	BUY	$127.65 - $183.11 $672,843 - $965,172	5,271 Added 11.79%	49,961 $6.74 Billion
Q2 2022 Aug 08, 2022	BUY	$123.25 - $186.24 $4.19 Million - $6.33 Million	34,000 Added 318.05%	44,690 $6.66 Million
Q1 2022 May 04, 2022	BUY	$126.25 - $231.85 $101,000 - $185,480	800 Added 8.09%	10,690 $1.82 Million
Q4 2021 Feb 02, 2022	BUY	$216.64 - $362.52 $67,158 - $112,381	310 Added 3.24%	9,890 $2.55 Million
Q2 2021 Aug 12, 2021	BUY	$113.32 - $241.49 $250,437 - $533,692	2,210 Added 29.99%	9,580 $2.15 Million
Q1 2021 May 11, 2021	BUY	$85.73 - $119.5 $631,830 - $880,715	7,370 New	7,370 $805,000

Others Institutions Holding BNTX

# of Institutions

363

Shares Held

39.6M

Call Options Held

3.01M

Put Options Held

2.01M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $29.1B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Banque Pictet & Cie Sa, based on Form 13F filings with the SEC.

News

Stay updated on Banque Pictet & Cie Sa with notifications on news.

Account

Banque Pictet & Cie Sa Bio N Tech Se Transaction History